Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Mega Lifesciences PCL's 3-Year RORE % for the quarter that ended in Sep. 2024 was -25.97%.
The industry rank for Mega Lifesciences PCL's 3-Year RORE % or its related term are showing as below:
BKK:MEGA's 3-Year RORE % is ranked worse than 70% of 980
companies
in the Drug Manufacturers industry
Industry Median: -1.555
vs BKK:MEGA: -25.97
Mega Lifesciences PCL 3-Year RORE % Historical Data
The historical data trend for Mega Lifesciences PCL's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mega Lifesciences PCL's 3-Year RORE %
For the Drug Manufacturers - Specialty & Generic subindustry, Mega Lifesciences PCL's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mega Lifesciences PCL's 3-Year RORE % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mega Lifesciences PCL's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Mega Lifesciences PCL's 3-Year RORE % falls into.
Mega Lifesciences PCL 3-Year RORE % Calculation
Mega Lifesciences PCL's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.
Mega Lifesciences PCL (BKK:MEGA) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Mega Lifesciences PCL 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Mega Lifesciences PCL's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Mega Lifesciences PCL manufactures and sells through independent distributors of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods as well as provides distribution services relating to such products. The company's product portfolio consists of health food supplements, branded prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. Its segments include Brands in which goods are manufactured and sold under brands owned by the group; Distribution in which the group provides logistical and marketing services for goods trading purposes and sale of goods manufactured by third parties; and OEM.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BKK:MEGA has been successfully added to your 